CTx-2103

About Cingulate Therapeutics

Cingulate Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, precision-timed therapeutics for central nervous system (CNS) disorders. Its core innovation is the Precision Timed Release™ (PTR™) platform, which enables the creation of single-dose, multi-pulse formulations designed to enhance efficacy and adherence. The company's strategy is to advance its late-stage pipeline in ADHD and anxiety, aiming to address significant unmet needs in large, established markets where current treatments suffer from pharmacokinetic limitations. Having gone public in 2021, Cingulate is now focused on executing its pivotal clinical trials to generate value-driving data.

About Cingulate

Cingulate is a neuroscience-focused biotech developing treatments for CNS disorders via its proprietary Precision Timed Release™ (PTR™) drug delivery platform. Its strategy is to create single-tablet, multi-release formulations that offer rapid onset and controlled duration of action, primarily targeting unmet needs in ADHD and anxiety. The company's most advanced candidates, CTx-1301 and CTx-1302, are in late-stage development for ADHD, representing its nearest-term value inflection points. As a pre-revenue, publicly traded entity, Cingulate's progress is measured by clinical milestones and its ability to navigate a competitive therapeutic landscape.

Therapeutic Areas

Other Generalized Anxiety Disorder (GAD) Drugs